Replimune Group (REPL)
(Delayed Data from NSDQ)
$6.41 USD
-0.32 (-4.75%)
Updated May 10, 2024 04:00 PM ET
After-Market: $6.41 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Replimune Group, Inc. [REPL]
Reports for Purchase
Showing records 21 - 40 ( 191 total )
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
As The Dust Settles -- Sifting Through The Biotech Carnage, We See Opportunity
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Fiscal Q3 Financials; CERPASS Topline Pushed to Q3:23
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
F3Q23 Financials Reported; Adjusting PT Up to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP1 Data Update; Collaboration Inked With Roche For RP3; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP1 IGNYTE Melanoma Data on Fire; RP2/3 Robust Ph 2 Development Plan Confirmed
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Several Near-Term Data Catalysts; FY2Q23 Financials; Modulating PT to $48
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
2Q22: Pivotal Trials Progressing; Readout Soon. Cash Secured into 2025.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Numerous Catalysts Slated to Accrue; F1Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; CERPASS Target Enrollment Reached; Interim IGNYTE Data Q4:22
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R